Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

Launched by AKIVA MINTZ · Jun 1, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new imaging technique called ultralow dose PET scanning to better detect Alzheimer’s disease, mild cognitive impairment, and other types of dementia. The main goal is to see if researchers can reduce the amount of radiation exposure by 10 to 100 times compared to current methods. Participants will receive a small injection of a radioactive substance, either 18F-Florbetapir or 18F-Flutemetamol, and then undergo imaging on a special PET scanner that is designed to be more sensitive. The entire process may take up to three hours.

To join the study, participants must be at least 18 years old and able to understand and agree to the study procedures. Women who can become pregnant must have a negative pregnancy test and should not be pregnant or breastfeeding. Some individuals may not be eligible if they have had too much radiation exposure from other studies or if they experience severe claustrophobia or certain medical conditions. If you decide to participate, you’ll help researchers find safer ways to detect and monitor dementia-related conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years.
• • 2. Ability to provide informed consent and comply with study procedures.
• 3. For female participants:
• • Must not be pregnant or breastfeeding.
• • Negative pregnancy test required for women of childbearing potential.
• Exclusion Criteria:
• • 1. Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).
• • 2. More than four prior enrollments in this study.
• • 3. Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
• • 4. Pregnant or breastfeeding individuals (negative pregnancy test required)
• • 5. Inability to provide informed consent
• • 6. Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.